Medroxyprogesterone

Details About Generic Salt ::  Medroxyprogesterone 

Main Medicine Class:: #N/A   Sub Medicine Class ::  #N/A

8G. PROGESTINS AND ANTI-PROGESTINS in 8. ENDOCRINE/STEROID HORMONES & METABOLIC SYSTEM
MEDROXYPROGESTERONE
PROGESTIN | CONTRACEPTIVE
also comes under 11A. Contraceptive Drugs in 11. Reproductive System,   11B. Drugs for Erectile Dysfunction/Libido/Infertility in 11. Reproductive System
PK: A: Well absorbed (PO), Slow (IM) M: Hepatic E: Urine

Indications & Dose: CONTRACEPTION Combination therapy IM Adult 25mg with estradiol cipionate (5mg) once monthly | Mono therapy IM Adult 150mg q13wk | SC Adult 104mg q12-14wk. First Inj during first 5 days of normal menstrual period or first 5 postpartal days if patient is not breastfeeding or during 6th postpartal wk if patient is breastfeeding exclusively | DYSFUNCTIONAL UTERINE BLEEDING PO Adult 5-10mg/day 5-10 days starting on day 16 or 21 of menstrual cycle | ENDOMETRIOSIS Mild-to-moderate PO Adult 10mg TID 90 days | Mild-to-moderate IM Adult 50mg/wk or 100mg q2wk 6 month | SC Adult Suspension: 104mg q12-14wk | PREVENTION OF ESTROGEN-RELATED ENDOMETRIAL CHANGES PO Adult Monophasic regimen: 1.5mg/day with 0.3mg/day conjugated estrogen or 1.5mg/day with 0.45mg/day conjugated estrogen or 2.5 or 5mg/day with 0.625mg/day conjugated estrogen. Biphasic regimen: 5 mg/day on days 15-28 of cycle with 0.625mg/day conjugated estrogens | RENAL/ENDOMETRIAL CANCER Adjuvant therapy IM Adult Initially 400mg-1g/wk, if improvement occurs, dose may be reduced to 400mg/month | SECONDARY AMENORRHEA PO Adult 5-10mg/day 5-10 days, starting at any time during menstrual cycle. However, usually started between the 16th & 21st day of menstrual cycle | SUPPRESSION OF LIBIDO IM Adult 300mg/wk

Contra: Hypersensitivity, history of/current thrombophlebitis, venous thromboembolic disorders, cerebral vascular disease, severe hepatic dysfunction/disease, breast carcinoma/other estrogen/ progesterone-dependent neoplasia, undiagnosed vaginal bleeding, missed abortion

Precautions: CVD, history of depression, diseases exacerbated by fluid retention, asthma, epilepsy, migraine, DM

ADR: Serious: Angioedema, osteoporosis, thrombophlebitis, pulmonary embolus, rectal bleeding, retinal thrombosis, syncope, seizure, arthralgia, edema, dysmenorrhea, Others: dizziness, headache, nervousness, depression, fatigue, insomnia, nausea, bloating, leukorrhea, vaginitis, atrophy, pain, backache, leg cramps, weakness

DDI: Serious Tamoxifen levels reduced, Aminoglutethimide reduces drug levels

Monitor: Physical exam with reference to breasts & pelvis, signs & symptoms of thromboembolic disorders, depression, glucose in patients with diabetes, BMD, BP